These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8440292)

  • 21. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Clin Neurol Neurosurg; 1992; 94(3):205-11. PubMed ID: 1327609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
    Modi NB; Mittur A; Rubens R; Khanna S; Gupta S
    Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical design and development of a Sinemet controlled-release formulation.
    Dempski RE; Scholtz EC; Oberholtzer ER; Yeh KC
    Neurology; 1989 Nov; 39(11 Suppl 2):20-4. PubMed ID: 2685648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report.
    Karstaedt PJ; Pincus JH; Coughlin SS
    Arch Neurol; 1991 Apr; 48(4):402-5. PubMed ID: 2012514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of continuous-release carbidopa/levodopa.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1994; 17 Suppl 2():S1-6. PubMed ID: 9358189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
    Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged serum levodopa levels with controlled-release carbidopa-levodopa in the treatment of Parkinson's disease.
    Hutton JT; Albrecht JW; Román GC; Kopetzky MT
    Arch Neurol; 1988 Jan; 45(1):55-7. PubMed ID: 3276299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steady plasma levodopa concentrations required for good clinical response to CR-4 in patients with 'on-off'.
    McHale DM; Sage JI; Sonsalla PK; Heikkila RE; Duvoisin RC
    Eur Neurol; 1990; 30(2):90-2. PubMed ID: 2340841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study.
    Sage JI; Mark MH
    Clin Neuropharmacol; 1988 Apr; 11(2):174-9. PubMed ID: 3378226
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
    Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
    J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa.
    Bowes SG; Dobbs RJ; Henley M; Charlett A; O'Neill CJ; Nicholson PW; Purkiss AG; Weller C; Dobbs SM
    Eur J Clin Pharmacol; 1992; 43(5):483-9. PubMed ID: 1483485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diurnal differences in response to oral levodopa.
    Frankel JP; Pirtosek Z; Kempster PA; Bovingdon M; Webster R; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):948-50. PubMed ID: 2283524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill
    LeWitt PA; Giladi N; Navon N
    Parkinsonism Relat Disord; 2019 Aug; 65():131-138. PubMed ID: 31176632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.
    Contin M; Riva R; Martinelli P; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1998 Jun; 54(4):303-8. PubMed ID: 9696954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease.
    Lieberman A; Gopinathan G; Miller E; Neophytides A; Baumann G; Chin L
    Eur Neurol; 1990; 30(2):75-8. PubMed ID: 2340838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
    Rondot P; Ziegler M; Aymard N; Teinturier A
    Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease--an open evaluation of efficacy and safety.
    Bulling MT; Wing LM; Burns RJ
    Aust N Z J Med; 1991 Aug; 21(4):397-400. PubMed ID: 1953526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.